Antiretroviral therapy is recommended for all HIV-infected individuals regardless of CD4 count to decrease morbidity and mortality associated with HIV infection.
Goals of antiretroviral treatment are suppression of viral load for maximum possible duration, restore & preserve immunologic function, reduce HIV-related morbidity & mortality and prevent HIV transmission.
Urgent initiation of antiretroviral treatment is recommended in the following individuals: pregnant women, patients w/ HIV with coinfections (HBV, HCV, active tuberculosis), AIDS-defining illness, HIV-associated nephropathy, low CD4 counts, acute opportunistic infections and HIV HBV with evidence of chronic liver disease.
The once-daily single-tablet combination therapy comprising darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) yields high virologic response rates over 96 weeks in patients with HIV-1, regardless of the presence of neurologic and/or psychiatric comorbidities (NPCs), a subgroup analysis presented at the AIDS 2020 virtual conference has shown.
Switching to a single-tablet triple-drug combination comprising bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is well tolerated while continuing to provide virologic suppression through to 48 weeks in elderly people (aged ≥65 years) living with HIV (PLWH), shows a pooled analysis presented at the AIDS 2020 virtual conference.
The benefit of using dolutegravir for HIV treatment in pregnant women outweighs the risk. This is the message delivered by two studies presented at the 23rd International AIDS Conference, which have shown that the drug induces rapid viral suppression and brings a slight but nonsignificant risk of neural tube defects (NTDs) compared with other antiretrovirals.
Current three-drug combination antiretroviral therapy (ART) regimens have proven to be highly effective, and the use of the relatively inexpensive rilpivirine (RPV) appears to have considerably better tolerability profile than efavirenz or protease inhibitors in regimens containing abacavir plus lamivudine (ABC/3TC) for treatment-naïve patients, offering a good, less costly approach to suppressing HIV, as shown in a Singapore study.
The combination of dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide fumarate (TAF) has superior virologic efficacy and safety compared with an efavirenz (EFV)/FTC/tenofovir disoproxil fumarate (TDF) combination in pregnant women living with HIV (WLHIV), results of the IMPAACT 2010/VESTED* trial showed.
The second HIV patient to successfully undergo stem cell transplantation is still in remission, a good 30 months after stopping antiretroviral therapy (ART) — raising hope that curing HIV is a possibility.
The gap in overall life expectancy between people with HIV (PWH) and those without HIV has narrowed over time, particularly among optimally treated PWH. However, PWH still have fewer comorbidity-free years than those without HIV, according to a study presented at CROI 2020.
Dr Dariusz P. Olszyna, a senior consultant at the Division of Infectious Diseases, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the importance of early detection to prevent the spread and complications related to sexually-transmitted infections (STIs).
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.